Good morning!

Huge thanks to Paul for covering for me yesterday, after I suffered severe travel delays.

Speaking of yesterday's report, Paul added a further six sections in the evening, so it's now an omnibus report. Here's the link.

Some stories I'm covering today (list evolving):

One of my activities on Monday was a recorded discussion at the offices of IG Group (LON:IGG).

Chris Boxall and I pondered the merits of H & T (LON:HAT), Ramsdens Holdings (LON:RFX), AdEPT Technology (LON:ADT), Pressure Technologies (LON:PRES), Duke Royalty (LON:DUKE), Park (LON:PARK), Quartix Holdings (LON:QTX), Rosenblatt (LON:RBGP) and PCF (LON:PCF). (I am long IGG, HAT, DUKE, PARK, PCF).

We were encouraged to disagree with each other, for the sake of good television! Here's the link.

Before getting into Wednesday's news, there was an announcement at Creightons (LON:CRL) yesterday:

Creightons (LON:CRL)

  • Share price: 35p (+6% on Tuesday)
  • No. of shares: 62.5 million
  • Market cap: £22 million

Acquisition of Balance Active Formula

(Please note that I have a long position in CRL.)

By the time you read this, Creightons is likely to have published its results for FY March 2019.

In advance of that, the company has released some details on a small acquisition. The purchase price isn't given.

What has it bought?

Creightons now owns "the brand equity, customer list and existing stock" of Balance Active Formula (BAF). 


This is a skincare specialist whose products include Snake Venom Wrinkle-Freeze Serum and Dragon's Blood Instant Eyelift Balm.

The announcement…

Unlock this Article with a 14 day free trial

or Unlock with your email

Already have an account?
Login here